ABL Diagnostics, the French molecular biology company listed on the Euronext Paris (Euronext: ABLD – ISIN: FR001400AHX6) has released a revolutionary genotyping kit, DeepChek® Assay HIV-1 Full PR/RT/INT Drug Resistance, in a bid to strengthen its expertise and leadership in HIV drug resistance testing. The new kit targets the protease, reverse transcriptase and integrase genes in a single PCR…